ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 91

Type I IFN Production Is Induced By Non-Haematopoietic Tissue Cells but Not Plasmacytoid Dendritic Cells in Preclinical Autoimmunity and SLE

Antonios Psarras1,2,3, Adewonuola Alase1, Agne Antanaviciute4, Ian Carr4, Miriam Wittmann1,2, George C Tsokos5, Paul Emery1,6 and Edward M Vital1,2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 3Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, 4Leeds Institute for Data Analytics, University of Leeds, Leeds, United Kingdom, 5Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 6Leeds Musculoskeletal Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Autoimmunity, Interferons and systemic lupus erythematosus (SLE), Lupus

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE is characterized by persistently high type I IFN activity. Plasmacytoid dendritic cells (pDCs) produce large amounts of IFNs in viral infections in response to nucleic acids and they have therefore been postulated to be the main source of type I IFNs in SLE. However, the precise role of pDCs in autoimmunity still remains unclear. The aim of this study was to investigate the source of type I IFN in patients with established SLE and preclinical autoimmunity.

Methods: Patients with SLE meeting 2012 ACR/SLICC criteria and healthy donors were recruited alongside therapy-naïve individuals presenting with ANA and 1 clinical symptom (At-Risk). IFN activity was evaluated by a score of IFN-responsive genes in the peripheral blood using TaqMan. pDCs were immunophenotyped and studied in vitro for production of cytokines and induction of T cell responses using flow cytometry. pDCs were sorted and sequenced using high-sensitive RNA sequencing. IFN expression was visualised in skin biopsies using in situ hybridisation. Keratinocytes were isolated from fresh skin biopsies and cultured in vitro; IFN production was measured by qPCR and ELISA.

Results: Most of SLE and At-Risk patients had increased IFN activity, which correlated with disease activity. In contrast, circulating pDCs were decreased in both SLE and At-Risk patients and their numbers did not correlate with any clinical features or IFN status. In vitro stimulation with TLR9 or TLR7 agonists revealed that pDCs from SLE and At-Risk patients could not produce IFN-α and TNF-α. In addition, they induced significantly less T cell activation and proliferation compared to pDCs from healthy donors. RNA-seq data analysis showed an upregulation of IFN-responsive genes in most of the SLE and At-Risk pDCs as well as pathways related to immune regulation and senescence but not transcripts of any IFN subtypes. Phenotypically, SLE pDCs were characterised by increased telomeric erosion. In situ hybridization revealed high IFN expression in the epidermis but not in lymphocyte-infiltrating areas of lesional biopsies from SLE patients. High expression of IFN was also observed in epidermis of At-Risk individuals without any signs of cutaneous inflammation. In vitro stimulation of freshly isolated keratinocytes from these also showed a notable increase in IFN production.

Conclusion: In SLE, non-haematopoietic tissue resident cells are a dominant source of IFN and this is present prior to clinically overt disease. Meanwhile, the professional IFN-producing pDCs have lost their immunogenic properties. These findings suggest an important role for tissue resident cells in autoimmunity and may facilitate novel therapeutic interventions.


Disclosure: A. Psarras, None; A. Alase, None; A. Antanaviciute, None; I. Carr, None; M. Wittmann, Novartis, 5,Janssen, 5,AbbVie Inc., 5,Celgene Corporation, 5; G. C. Tsokos, Janssen, 5,Silicon Pharmaceuticals, 9,ABPRO, 9; P. Emery, Bristol-Myers Squibb, 2, 5,Pfizer, Inc., 2, 5,Roche, 2, 5,Novartis, 5,UCB, Inc., 5,Abbott, 2, 5,Merck & Co., 2; E. M. Vital, Roche, 2, 5,GlaxoSmithKline, 2, 5,AstraZeneca, 2, 5.

To cite this abstract in AMA style:

Psarras A, Alase A, Antanaviciute A, Carr I, Wittmann M, Tsokos GC, Emery P, Vital EM. Type I IFN Production Is Induced By Non-Haematopoietic Tissue Cells but Not Plasmacytoid Dendritic Cells in Preclinical Autoimmunity and SLE [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/type-i-ifn-production-is-induced-by-non-haematopoietic-tissue-cells-but-not-plasmacytoid-dendritic-cells-in-preclinical-autoimmunity-and-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/type-i-ifn-production-is-induced-by-non-haematopoietic-tissue-cells-but-not-plasmacytoid-dendritic-cells-in-preclinical-autoimmunity-and-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology